SUMMARY Forty normal women had thrombin-stimulated platelet malondialdehyde (MDA) production measured during their menstrual cycle. Twenty women in this group were taking the combined oral contraceptive pill (OCP). Platelet MDA production was found to fall by 30 O% during normal menstruation and the week when the subjects were not taking a combined OCP, but it remained constant throughout the remainder of the cycle. No significant change in initial platelet aggregation response to stimulation by thrombin, change in plasma thrombin clotting time, plasma heparin neutralising activity (HNA), or plasma antithrombin III (AT-III) activity was seen when the platelet MDA production was reduced. The bleeding time results showed some variation throughout the menstrual cycle but these did not appear to be related to the variation in platelet MDA production.
MDA (malondialdehyde) is a byproduct of prostaglandin metabolism and it has been used as an indicator of the activity of the enzyme cyclooxygenase in platelets. The enzyme is irreversibly inhibited by aspirin and this provides a means of measuring the platelet regeneration time after aspirin ingestion.1 When MDA production in appropriately stimulated platelets after aspirin ingestion reaches the pre-aspirin level, it is assumed that the entire population of aspirin-inhibited platelets has been removed from the circulation and replaced by new platelets. The reliability of this method of measuring platelet regeneration time depends on a steady platelet MDA production over the required period.
This study was stimulated by a report that the activity of the enzymes involved in platelet prostaglandin and thromboxane synthesis might vary throughout the menstrual cycle and be influenced by the OCP (oral contraceptive pill).2 We therefore decided to investigate whether a similar variation occurred in platelet MDA production both in users and non-users of the OCP during the menstrual cycle.
Accepted for publication 5 November 1980 595 Subjects and methods Twenty "non-pill" users and 20 taking the combined OCP gave fully-informed consent to having blood taken one and two days before menstruation and then on days 1-7, 14 and 21 of the menstrual cycle, for the measurement of platelet MDA concentrations. Bleeding times were measured on the same days in 10 of the "non-pill" and 10 of the "pill" users. The platelet aggregation response to thrombin, plasma heparin neutralising activity (HNA), and plasma antithrombin III (AT III) activity were measured in these women one and two days before menstruation and on days 1-7 of the menstrual cycle.
All the "non-pill" users had a normal cycle with no history of menorrhagia or bleeding disorders. Of the 20 "pill" users, 10 were taking Eugynon-30 (ethinyloestradiol 30 All the blood samples were taken at approximately the same time each day. A total of 30 ml of nonfasting venous blood was removed and anticoagulated with 3-8% sodium citrate solution (1 vol of citrate to 9 vol of blood). This was centrifuged at 200 g for 10 min at room temperature to obtain plateletrich plasma. The supernatant was removed and the remainder of the blood centrifuged at 1400 g for 15 min to obtain platelet-poor plasma.
MEASUREMENT OF PLATELET MDA PRODUCTION
The platelet count of the platelet-rich plasma was estimated using a Coulter Thrombocounter. 50 pul thrombin (25 U/ml) and 50 ,tl streptokinase (2500 U/ml) were added to Eppendorf tubes placed in a water bath at 370C. 400 ,ul of platelet-rich plasma was added and the tubes mixed at three-minute intervals. The reaction was stopped after 15 min by the addition of 500 /tl of 10% solution of trichloracetic acid. The tubes were centrifuged at 9000 g for two minutes in an Eppendorf 3200 centrifuge. A 400 ,ul aliquot of the supernatant was placed for 30 min in a water bath at 70°C with 400 ,ul of 0 53% solution of thiobarbituric acid in water. Deionised water (1-2 ml) was then added to each sample and the fluorescence of the thiobarbituric acid-malondialdehyde complex was read in a spectrofluorimeter at an excitation wavelength of 510 nm and emission wavelength of 553 nm.3 The results were read off a standard curve which was obtained by using MDA solutions in the range 0-1000 pmol/ml instead of platelet-rich plasma, but omitting the thrombin and streptokinase incubation step. The sample fluorescence was then converted into pmol MDA/108 platelets.
Antithrombin III activity was estimated by a chromogenic substrate method.4
Heparin neutralising activity of plasma was estimated as described by Donati et al.5
Platelet aggregation to thrombin and thrombin clotting time. A Payton dual channel aggregometer at 37°C was used. The platelet count of the plateletrich plasma was adjusted to 200 000-250 000 mm3 (200-250 x 109/l) and the platelets were then aggregated with thrombin using a final concentration 0-2 U/ml. The rate and maximum of aggregation was measured. The thrombin clotting time was estimated from the time lapse between the addition of thrombin to platelet-rich plasma and the appearance of fibrin in the cuvette causing a sharp increase in optical density of the plasma.
Bleeding time. This was measured by the Template method using a Simplate bleeding time device (General Diagnostics).
Results
PLATELET MDA PRODUCTION Table 2 shows that the amount of MDA produced by platelets stimulated with thrombin fell by approximately 30 % during menstruation in both "non-pill" users and those on the combined OCP. These values had returned to premenstrual concentrations by the seventh day of the menstrual cycle and no further fluctuations were seen during the rest of the cycle. This table also shows that the absolute amount of The Figure illustrates the bleeding time throughout the menstrual cycle in the "non-pill" users. All the results were within the normal range for the Template method (3-9 min). A variation throughout the cycle was noted but the results could not be correlated with the change in platelet MDA concentrations. The bleeding times in those on the combined OCP showed less variation and were generally slightly longer than in the other group but still within the normal range.
Discussion
Our study shows that the amount of platelet MDA produced after stimulation with thrombin decreases during the first three days of menstruation, then gradually returns to premenstrual values by day 7 and remains fairly constant for the rest of the cycle. A remarkably similar pattern is observed in the "pill" users suggesting that the decrease in the first week of the cycle may not be a direct result of hormonal influences, but may be related to uterine bleeding.
Survival of 51chromium-labelled platelets in Days of menstrual cycle -_ Bleeding time (mnin) throughout the menstrual cycle iti 10 "non-pill" users.
"non-pill"users during menstruation was found to be normal and no excess radioactivity could be demonstrated in the menstrual fluid.7 This suggests that if any platelets were taking part in haemostatic events in the menstruating uterus, they might have been reabsorbed from the uterus into the general circulation without destruction. Alternatively the number of platelets taking part in uterine haemostasis might be insignificant. The role of platelets in uterine haemostasis is not doubted as menorrhagia is a common problem in both quantitative and qualitative platelet disorders. 8 The scarcity of platelets in the histological examination of the menstruating uterus7 might be due to the reversibility of platelet involvement in uterine haemostasis. That Table 3 Results of measurements on plasma heparin neutralising activity (HNA), antithrombin I1 activity (AT III), platelet aggregation response to thrombin and thrombin clotting time in twenty women ("pill" group = 10, "non-pill" group = 10) 
